Items where Division is "Bacteriology" and Year is 2023

B

Balasubramanian, M and Munishankar, S and Thiruvenkadam, K and Dusthackeer, A (2023) Myoinositol and methyl stearate increases rifampicin susceptibility among drug- resistant Mycobacterium tuberculosis expressing Rv1819c. Myoinositol and methyl stearate increases rifampicin susceptibility among drug- resistant Mycobacterium tuberculosis expressing Rv1819c, 101(4) (883-95).

C

Christy Rosaline, Nirmal and Sam Ebenezer, Rajadas and Balasubramanian, Mahizhaveni and Magdaline, Divya and Chilamakuru, Naresh Babu and Rajkumar, Dinesh and A, Radhakrishnan and Ramalingam, Paraman and Mondal, Rajesh and Azger, Dustackeer (2023) Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c. Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c, 157 (2). pp. 192-203. ISSN 0971-5916

Q

Quinn, Frederick and Mondal, Rajesh and Dusthackeer V. N., Azger and Kannan, Palaniyandi and Singh, Amit Kumar and Thiruvengadam, Kannan and Manikkam, Radhakrishnan and A. S., Shainaba and Balasubramanian, Mahizhaveni and Elango, Padmasini and Ebenezer Rajadas, Sam and Bharadwaj, Dinesh and Arumugam, Gandarvakottai Senthilkumar and Ganesan, Suresh and Kumar A. K., Hemanth and Singh, Manjula and Patil, Shripad and U. C. A., Jaleel and Doble, Mukesh and R., Balagurunathan and Tripathy, Srikanth Prasad and Kumar, Vanaja (2023) In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor. PLOS ONE, 18 (3). e0282454. ISSN 1932-6203

S

Sivakumar, Shanmugam (2023) Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity. Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity, 14(3) (40584).

T

Thangavel, K and Vadivel, SD and Thiruvengadam, K. and Sivaramakrishnan, G and Padmapriyadarsini, C and Shanmugam, S (2023) Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India, 59(6) (1005).